Henry Schein
HSIC · What the business does, what can go wrong, and how options sellers approach it
What it does
Henry Schein is a distributor of products and services for office-based dental and medical practices. It supplies everyday consumables, equipment and related technical services, and it also sells practice management software and other technology tools. Its customers are mostly small and mid-sized practices, along with other alternative sites of care.
The company reports in three areas: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology.
How it makes money
Most revenue comes from distribution. Henry Schein buys products from manufacturers, and also sells its own corporate-brand items, then delivers them to practices. It earns the spread between what it pays and what it charges.
Value-added services add to that, including financial services, continuing education and practice consulting. The specialty products and technology businesses can carry different margins from distribution, since software and specialty items work differently from moving boxes of supplies.
Why investors own it
- Dental and medical practices reorder supplies steadily, which can make demand fairly recurring.
- Scale in purchasing and logistics can be hard for smaller rivals to match.
- Software and services can deepen customer relationships.
- Some investors like exposure to healthcare spending that is less tied to hospitals.
What can go wrong
- Distribution is a competitive, low-margin business, and pricing pressure can squeeze profits.
- Elective dental procedures can slow when consumers cut back or when staffing is tight in practices.
- Large customers may consolidate and gain bargaining power.
- Supply chain disruptions, tariffs or shipping costs can raise expenses.
- Acquisitions can disappoint or be hard to integrate.
- Cyber incidents are a risk for a company that handles orders, data and software.
What to watch
- Organic sales growth in dental and in medical
- Operating margin trends
- Growth in the technology and value-added segments
- Corporate-brand and specialty product mix
- Patient traffic and practice activity in dental
- Free cash flow and share repurchases
- Management commentary on acquisitions and integration
Options income angle
Options on HSIC are generally available, but they tend to be less active than those on large, widely traded names. Bid-ask spreads can be wider, especially on strikes far from the current price or on longer-dated expirations, so check open interest and volume before trading.
Implied volatility tends to rise ahead of quarterly earnings and when the market reacts to changes in guidance, dental demand, or healthcare policy. It usually settles after those events pass.
One caution: a stock like this can move sharply on an earnings surprise. Someone selling covered calls could miss large upside, and someone selling puts could be assigned shares after a gap down.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 27, 2025, filed February 24, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Henry Schein grew net sales to $13,184 million in 2025 and kept profit roughly steady, while gross margin slipped and debt rose. The filing also covers a change of CEO, KKR's growing stake in the company, and uncertainty from tariffs and Medicaid changes. Management is in the middle of a restructuring that it expects to finish at the end of 2027.
How the business did
- Net sales were $13,184 million, up from $12,673 million, an increase of 4.0%. Internal growth (growth excluding acquisitions and currency effects) was 2.6%.
- Operating income was $653 million versus $621 million. Net income attributable to Henry Schein, Inc. was $398 million versus $390 million. Gross margin fell to 31.1% from 31.7%, which management tied to promotions and product mix.
- Global Technology sales rose 7.1% and Global Specialty Products rose 6.7%. Global Distribution and Value-Added Services rose 3.5%. Specialty Products growth came from implants, biomaterials and orthopedics, partly offset by lower orthodontic sales.
- Net cash from operations was $712 million versus $848 million. Management said 2024 had been lifted by unusually high cash collections after the 2023 cyber incident. Interest expense was $150 million versus $131 million on higher borrowings, and total debt was $3,107 million versus $2,536 million.
- The company completed a $250 million accelerated share repurchase and had $780 million available for future buybacks.
Risks specific to this company
- KKR: KKR invested $250 million in May 2025 and has two seats on the board. In November 2025 its permitted ownership limit was raised from 14.9% to 19.9%. The filing warns this could create uncertainty about strategy and conflicts with customers or suppliers.
- CEO transition: Stanley M. Bergman retires as CEO on March 1, 2026 and stays as Chairman. Frederick M. Lowery becomes CEO on March 2, 2026. The filing says leadership transitions can be hard to manage.
- Medicaid and tariffs: Management says the One Big Beautiful Bill Act (OBBBA) is expected to reduce Medicaid enrollment. Together with tariffs, it will likely hurt utilization, Medicaid payment and production costs. Tariffs did not materially affect 2025 results, but they briefly slowed U.S. dental equipment sales.
- Supplier dependence: Its top 10 distribution suppliers made up about 24% of purchases, and the largest was about 4%. The company generally has no long-term contracts with suppliers, and supplier rebates can be cut or made harder to earn.
- Cyber exposure: The October 2023 incident disrupted North American and European distribution. The filing says the company may now be seen as a more vulnerable target.
- Competition from large buyers: Dental service organizations and group purchasing organizations can get better pricing and may buy directly from manufacturers.
What management is watching
- The 2025 – 2027 BOLD+1 Strategic Plan, which focuses on growing specialty brands and technology and value-added services, both organically and through acquisitions.
- The 2024 restructuring plan. It carried $105 million of charges in 2025 and is expected to run through the end of 2027. Management has not estimated the 2026 and 2027 charges.
- Corporate technology spending behind the launch of its Global E-Commerce Platform, which raised operating costs.
- Tariffs, the OBBBA and Medicaid funding, which management says remain unclear in scope and timing.
- Measures the filing highlights: internal growth in local currency, segment gross margins and segment operating expenses (which exclude items like restructuring), days sales outstanding (how long customers take to pay) of 44.8 days versus 47.3 days, and inventory turns of 4.8 versus 5.0.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 26, 2026, filed November 3, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Henry Schein reported net sales of $3,471 million for the quarter ended September 26, 2026, up from $3,339 million a year earlier. Operating income rose to $193 million from $164 million. The quarter included a net benefit of $28 million from refunds of previously paid IEEPA tariffs, and the company expects more such benefit in the fourth quarter.
How the business did
- Sales: Net sales rose 4.0% in the quarter, made up of internal growth of 3.1%, acquisition growth of 0.7% and a foreign exchange increase of 0.2%. For the nine months, net sales were $10,297 million versus $9,747 million, up 5.6%.
- Segments: Global Dental Merchandise sales rose 7.0% to $1,295 million. Global Specialty Products rose 6.1%, helped by value and premium implants. Global Technology rose 5.2%, with cloud-based practice management software driving local currency growth of 6.5%. Global Medical rose only 1.1%, held back by lower sales of point of care diagnostic tests and vaccines tied to respiratory illness.
- Profit: Gross profit was $1,105 million, and gross margin (gross profit as a share of sales) was 31.8% versus 30.7%. The filing credits the tariff refunds, favorable business mix and value creation initiatives. Net income attributable to Henry Schein was $119 million versus $101 million. For the nine months it was $320 million versus $297 million. The year-earlier quarter included a $28 million benefit from remeasuring a previously held equity investment to fair value.
- Cash and capital: Net cash provided by operating activities was $306 million for the nine months versus $331 million, as working capital (receivables, inventory and other current assets) absorbed cash. Total debt was $3,524 million versus $3,107 million at December 27, 2025, and interest expense rose on increased borrowings. The company had $330 million available for future share repurchases.
What management is watching
- Tariffs: Management says tariffs had no adverse material impact on results in fiscal year 2025 or the nine months, but calls the trade environment volatile. It notes that the U.S. has put other tariff measures in place since the Supreme Court invalidated certain IEEPA tariffs.
- Restructuring and advisory costs: The 2024 restructuring plan is expected to finish by the end of 2027. Charges were $22 million in the quarter versus $34 million. The company has not estimated the charges for 2026 through 2027. Costs tied to shareholder advisory matters and value creation consulting were $18 million versus $10 million.
- Working capital and measures: Days sales outstanding (how long customers take to pay) rose to 46.6 days from 45.3. Inventory turns fell to 4.6 from 4.8. The company says sales tend to be stronger in the second half and that working capital needs run higher from the end of the third quarter into the first quarter. It points investors to internal growth in local currency, which strips out acquisitions and currency effects.
- Leadership: Effective November 4, 2026, Emmanuel Caprais succeeds Ronald N. South as Chief Financial Officer. Mr. South becomes Senior Advisor.
Follow HSIC in Kortex
The Kortex app shows HSIC's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.